IM Cannabis Corp (IMCC)
NASDAQ:IMCC
Want to see IMCC full AI Analyst Report?
Top Page
IM Cannabis Corp
(NASDAQ:IMCC)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.31
▼(-78.68% Downside)
Action:Upgraded
Date:06/02/26
The score is mainly weighed down by weak financial performance, particularly negative equity, ongoing operating losses, and a return to TTM cash burn. Technicals are mixed (above the 20-day average but below longer-term averages with a negative MACD), while valuation signals are constrained by a negative P/E and no dividend yield data.
Positive Factors
Strong German market position
IM Cannabis's EU‑GMP‑backed platform and rapid German sales growth provide durable access to the largest regulated EU medical cannabis market. High German share (>two‑thirds) and scale create distribution leverage, regulatory credibility, and potential margin stability as regulations remain supportive.
Negative Factors
Negative shareholders' equity
Negative equity materially reduces financial flexibility and distorts leverage metrics, increasing refinancing and covenant risk. With ~ $15M of debt and equity erosion, the company may face higher financing costs, restricted credit access, and greater likelihood of dilutive capital raises absent sustained profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong German market position
IM Cannabis's EU‑GMP‑backed platform and rapid German sales growth provide durable access to the largest regulated EU medical cannabis market. High German share (>two‑thirds) and scale create distribution leverage, regulatory credibility, and potential margin stability as regulations remain supportive.
Read all positive factors
IM Cannabis Corp (IMCC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.80M
Dividend YieldN/A
Average Volume (3M)72.27K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth-6.14%
EPS Growth-24.22%
CountryUS
Employees95
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-2.51
Shares Outstanding6,223,323
10 Day Avg. Volume74,089
30 Day Avg. Volume72,265
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-9.42
Price to Sales (P/S)0.15
P/FCF Ratio1.72
Enterprise Value/Market Cap17.81
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit4.42
Enterprise Value/Ebitda-6.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$62.75M
IM Cannabis Corp Business Overview & Revenue Model
Company Description
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers cannabis flowers and strain specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, and pressed ...
How the Company Makes Money
IM Cannabis generates revenue primarily by selling cannabis products in regulated markets through its operating subsidiaries. Key revenue streams typically include: (1) wholesale/B2B sales of dried flower and other cannabis products to licensed di...
IM Cannabis Corp Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The earnings call for IM Cannabis reflected a positive sentiment, with the company achieving net profitability and substantial growth in the German market, despite a decline in Israeli revenue and increased liabilities.Positive Updates
Net Profit Achieved in Q1 2025
IM Cannabis achieved a net profit of approximately $0.2 million in Q1 2025, marking a significant turnaround from a loss of $6 million in Q1 2024.
Negative Updates
Decline in Israeli Revenue
Revenue in Israel declined by 56% compared to Q1 2024, primarily due to the cancellation of the Oranim deal.
Read all updates
Q1-2025 Updates
Positive
Negative
Net Profit Achieved in Q1 2025
IM Cannabis achieved a net profit of approximately $0.2 million in Q1 2025, marking a significant turnaround from a loss of $6 million in Q1 2024.
Read all positive updates
Company Guidance
During the Q1 2025 earnings call, IM Cannabis reported a significant turnaround with a net profit of $0.2 million, contrasting with a $6 million loss in Q1 2024. The company achieved an adjusted EBITDA profit of $0.6 million, representing an improvement of almost $3 million compared to the previous year's loss of $2.2 million. Revenues increased by 4% to $12.5 million, driven by a remarkable 569% growth in the German market, which now represents 62% of total revenue. This growth in Germany offset a 56% decline in Israeli revenue. The gross margin improved by 87%, and gross profit surged 94% to $3.4 million, aided by strategic cost-cutting measures that reduced operating expenses by 56%. Total assets grew by 15%, reflecting increased trade receivables, inventory, and advances to suppliers. The company plans to continue financing operations through existing resources and available credit facilities while exploring additional capital sources.IM Cannabis Corp Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
18
Very Negative
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 44.12M | 54.73M | 54.03M | 48.80M | 54.34M | 34.05M |
| Gross Profit | 7.25M | 9.69M | 8.45M | 9.85M | 9.16M | 6.33M |
| EBITDA | -5.03M | -6.95M | -6.14M | -2.79M | -16.76M | 6.24M |
| Net Income | -11.09M | -11.32M | -10.59M | -9.50M | -188.89M | -17.76M |
Balance Sheet | ||||||
| Total Assets | 23.68M | 31.74M | 39.19M | 48.81M | 60.68M | 287.39M |
| Cash, Cash Equivalents and Short-Term Investments | 1.15M | 2.73M | 863.00K | 1.81M | 2.45M | 13.90M |
| Total Debt | 14.95M | 16.27M | 18.01M | 13.78M | 11.53M | 29.27M |
| Total Liabilities | 28.80M | 35.35M | 36.04M | 35.11M | 36.88M | 82.44M |
| Stockholders Equity | -5.05M | -858.00K | 5.24M | 14.47M | 22.65M | 201.24M |
Cash Flow | ||||||
| Free Cash Flow | -1.73M | 4.70M | -1.23M | -8.66M | -14.20M | -38.97M |
| Operating Cash Flow | -1.72M | 4.72M | -1.08M | -8.07M | -12.64M | -34.37M |
| Investing Cash Flow | -1.11M | -531.00K | -470.00K | -1.18M | -1.41M | -9.01M |
| Financing Cash Flow | 4.38M | 1.15M | 3.83M | 9.42M | 4.76M | 48.73M |
IM Cannabis Corp Technical Analysis
Neutral
1.44
Price Trends
0.32
Negative
0.67
Negative
1.20
Negative
Market Momentum
-0.01
Negative
49.31
Neutral
29.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMCC, the sentiment is Neutral. The current price of 1.44 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.32, and above the 200-day MA of 1.20, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 49.31 is Neutral, neither overbought nor oversold. The STOCH value of 29.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IMCC.
IM Cannabis Corp Risk Analysis
IM Cannabis Corp disclosed 1 risk factors in its most recent earnings report. IM Cannabis Corp reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IM Cannabis Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $365.47M | ― | -1.00% | ― | 1.57% | 89.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $36.61M | -0.76 | -122.57% | ― | -100.00% | 54.21% | |
49 Neutral | $643.47M | ― | -92.82% | ― | 3.82% | -29.80% | |
47 Neutral | $7.35M | -2.95 | -40.66% | ― | 2.00% | 94.31% | |
42 Neutral | $1.80M | -14.53 | -93.87% | ― | -6.14% | -24.22% |
* Healthcare Sector Average
IMCC
IM Cannabis Corp
0.29
-2.56
-89.68%
YCBD
cbdMD
0.75
-0.23
-23.47%
TLRY
Tilray
5.19
1.31
33.69%
SNDL
SNDL
1.43
0.14
10.85%
IXHL
Incannex Healthcare Limited Sponsored ADR
3.09
-2.28
-42.46%
IM Cannabis Corp Corporate Events
IM Cannabis Corp. Posts Q1 2026 Results, Cuts Expenses Amid Ongoing Losses
May 13, 2026
IM Cannabis Corp., a medical cannabis producer and distributor active in Israel and Germany, focuses on serving prescription patients via import, distribution, and retail pharmacy and online channels, supported by data-driven patient insights. In ...
IM Cannabis Raises US$550,000 via Convertible Notes and Warrants
May 7, 2026
On April 6 and May 7, 2026, IM Cannabis Corp. raised a total of US$550,000 in gross proceeds through two privately placed convertible notes with an institutional lender, each carrying an 8% annual interest rate, rising to 14% on default. The notes...
IM Cannabis Raises US$250,000 via Convertible Note and Warrants on April 6, 2026
Apr 6, 2026
On April 6, 2026, IM Cannabis Corp. entered into a note purchase agreement with an institutional investor to issue a US$250,000 convertible note and a warrant for up to 272,861 common shares. The net proceeds of approximately US$225,000 are earmar...
IM Cannabis Delivers 2025 Cash-Flow Turnaround and Eyes Defense-Tech Expansion
Mar 31, 2026
IM Cannabis Corp., a Nasdaq-listed medical cannabis operator with integrated distribution, retail and online platforms in Israel and Germany, reported its audited results for the year ended December 31, 2025. The company continues to position itse...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.